Home Sulfos sodium (4bS,8R,8aR)-8-carboxy-4b,8-dimethyl-2-(propan-2-yl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3-sulfonate

sodium (4bS,8R,8aR)-8-carboxy-4b,8-dimethyl-2-(propan-2-yl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3-sulfonate

CAS No.:
86408-72-2
Catalog Number:
AG0039L4
Molecular Formula:
C20H27NaO5S
Molecular Weight:
402.4801
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1g
98%
In Stock USA
United States
$13
- +
5g
98%
In Stock USA
United States
$44
- +
10g
98%
In Stock USA
United States
$82
- +
25g
98%
In Stock USA
United States
$163
- +
100g
98%
In Stock USA
United States
$450
- +
Product Description
Catalog Number:
AG0039L4
Chemical Name:
sodium (4bS,8R,8aR)-8-carboxy-4b,8-dimethyl-2-(propan-2-yl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3-sulfonate
CAS Number:
86408-72-2
Molecular Formula:
C20H27NaO5S
Molecular Weight:
402.4801
MDL Number:
MFCD26131248
IUPAC Name:
sodium;(4bS,8R,8aR)-8-carboxy-4b,8-dimethyl-2-propan-2-yl-5,6,7,8a,9,10-hexahydrophenanthrene-3-sulfonate
InChI:
InChI=1S/C20H28O5S.Na/c1-12(2)14-10-13-6-7-17-19(3,8-5-9-20(17,4)18(21)22)15(13)11-16(14)26(23,24)25;/h10-12,17H,5-9H2,1-4H3,(H,21,22)(H,23,24,25);/q;+1/p-1/t17-,19-,20-;/m1./s1
InChI Key:
RCVIHORGZULVTN-YGJXXQMASA-M
SMILES:
COC(=O)[C@@H]1CCC[C@]2([C@@H]1CCc1c2cc(c(c1)C(C)C)S(=O)(=O)[O-])C.[Na+]
UNII:
51MO2B2OSB
Properties
Complexity:
672  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
3  
Defined Bond Stereocenter Count:
0
Exact Mass:
402.148g/mol
Formal Charge:
0
Heavy Atom Count:
27  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
402.481g/mol
Monoisotopic Mass:
402.148g/mol
Rotatable Bond Count:
3  
Topological Polar Surface Area:
103A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
Title Journal
Safety and tolerability of bismuthyl ecabet suspension, a novel anti-ulcer agent, following single and multiple oral dose administration in healthy Chinese subjects. Clinical drug investigation 20120401
Effect of ecabet sodium treatment on urea breath test and stool antigen tests in volunteers with Helicobacter pylori infection. Journal of gastroenterology and hepatology 20120401
Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H. pylori infection. Internal medicine (Tokyo, Japan) 20110101
Ecabet sodium: a potential new agent in the management of distal colitis. Journal of gastroenterology and hepatology 20100701
Ecabet sodium promotes the healing of trinitrobenzene-sulfonic-acid-induced ulceration by enhanced restitution of intestinal epithelial cells. Journal of gastroenterology and hepatology 20100701
Quadruple therapy with ecabet sodium, omeprazole, amoxicillin and metronidazole is effective for eradication of Helicobacter pylori after failure of first-line therapy (KDOG0201 Study). Journal of clinical pharmacy and therapeutics 20100601
Characteristic pathological findings and effects of ecabet sodium in rat reflux esophagitis. World journal of gastroenterology 20090728
Identification of the metabolites of ecabet bismuth in rat bile by liquid chromatography-electrospray ionization-tandem mass spectrometry. European journal of mass spectrometry (Chichester, England) 20090101
Ecabet sodium induces neuronal nitric oxide synthase-derived nitric oxide synthesis and gastric adaptive relaxation in the human stomach. Journal of gastroenterology 20090101
Re-epithelialization of squamous epithelium for a radiation-induced rectal ulcer while giving an ecabet sodium enema. Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 20090101
Effects of ecabet sodium on acute mixed reflux esophagitis in rats. Scandinavian journal of gastroenterology 20090101
Comparison of an ecabet sodium and proton pump inhibitor (PPI) combination therapy with PPI alone in the treatment of endoscopic submucosal dissection (ESD)--induced ulcers in early gastric cancer: prospective randomized study. Hepato-gastroenterology 20090101
Determination of ecabet in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080301
H pylori eradication: a randomized prospective study of triple therapy with or without ecabet sodium. World journal of gastroenterology 20080214
High affinity of ecabet sodium for inflamed colonic mucosa in ulcerative colitis. Digestive diseases and sciences 20070601
Drug evaluation: TA-2711E in the treatment of active distal ulcerative colitis. Current opinion in investigational drugs (London, England : 2000) 20070501
Ecabet sodium prevents esophageal lesions induced by the reflux of gastric juice in rats. Inflammopharmacology 20070401
Efficacy of ecabet sodium enema on steroid resistant or steroid dependent ulcerative colitis. Gut 20061001
Efficacy and safety of ecabet sodium on functional dyspepsia: a prospective, double-blinded, randomized, multi-center controlled trial. World journal of gastroenterology 20060507
Comparison of the effects of cytoprotective drugs on human plasma adrenocorticotropic hormone and cortisol levels with continual stress exposure. Biological & pharmaceutical bulletin 20051101
Ecabet sodium raises plasma levels of calcitonin generelated peptide and substance P in healthy humans. The Journal of pharmacy and pharmacology 20050601
[Enema therapy for ulcerative colitis patients]. Nihon rinsho. Japanese journal of clinical medicine 20050501
Therapeutic effects of ecabet sodium, an antiulcer drug, on dextran sodium sulfate-induced ulcerative colitis in rats. Digestive diseases and sciences 20050501
Ecabet sodium prevents the delay of wound repair in intestinal epithelial cells induced by hydrogen peroxide. Journal of gastroenterology 20050501
Ecabet sodium inhibits Helicobacter pylori lipopolysaccharide-induced activation of NADPH oxidase 1 or apoptosis of guinea pig gastric mucosal cells. American journal of physiology. Gastrointestinal and liver physiology 20050201
Combination therapy of ecabet sodium and cimetidine compared with cimetidine alone for gastric ulcer: prospective randomized multicenter study. Journal of gastroenterology and hepatology 20030901
Inhibition of peptic ulcer relapse by ranitidine and ecabet independently of eradication of Helicobacter pylori: a prospective, controlled study versus ranitidine. Hepato-gastroenterology 20030101
Helicobacter pylori eradication therapy for the remnant stomach after gastrectomy. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20030101
Inhibition of Helicobacter pylori-induced nuclear factor-kappa B activation and interleukin-8 gene expression by ecabet sodium in gastric epithelial cells. Helicobacter 20030101
Ecabet sodium attenuates reactive oxygen species produced by neutrophils after priming with bacterial lipopolysaccharides. Luminescence : the journal of biological and chemical luminescence 20030101
[QOL and the older people with peptic ulcer]. Nihon rinsho. Japanese journal of clinical medicine 20020801
Chemistry and mechanism of urease inhibition. Current medicinal chemistry 20020701
[Ecabet sodium (ECA) + PPI + AMPC therapy for clarithromycin-resistant Helicobacter pylori infections]. Nihon rinsho. Japanese journal of clinical medicine 20020201
[Ecabet sodium]. Nihon rinsho. Japanese journal of clinical medicine 20020201
[Effect of antiulcer agents on the urea breath test--Comparison between rebamipide and ecabet sodium]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20020101
Single administration of ecabet sodium diminishes the level of delta-13CO2 in urea breath test. Journal of gastroenterology 20020101
Effects of ecabet sodium, an antiulcer drug, on gastric adaptive relaxation in isolated guinea-pig stomachs. Drugs under experimental and clinical research 20020101
Effects of anti-ulcer agents on ethanol-induced gastric mucosal lesions in D-galactosamine-induced hepatitis rats. Arzneimittel-Forschung 20020101
Effects of the anti-ulcer agents ecabet sodium, cimetidine and sucralfate on acetylsalicylic acid-induced gastric mucosal damage deteriorated by renal failure in rats. Arzneimittel-Forschung 20020101
Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. Alimentary pharmacology & therapeutics 20010801
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scandinavian journal of gastroenterology 20010701
Mucosal protective effects of ecabet sodium: pepsin inhibition and interaction with mucus. Clinical science (London, England : 1979) 20010401
Effect of ecabet sodium enema on mildly to moderately active ulcerative proctosigmoiditis: an open-label study. The American journal of gastroenterology 20010301
Ecabet sodium inhibits the ability of Helicobacter pylori to induce neutrophil production of reactive oxygen species and interleukin-8. Journal of gastroenterology 20010301
Properties